查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1996531

甲癣治疗市场：2026-2032年全球市场预测（依药物类型、活性成分、剂型、治疗环境、年龄层、性别、疾病严重程度及分销管道划分）

Onychomycosis Treatment Market by Drug Type, Active Ingredient, Formulation, Treatment Setting, Age Group, Gender, Disease Severity, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，甲癣治疗市场价值将达到 22.9 亿美元，到 2026 年将成长至 25.2 亿美元，到 2032 年将达到 47 亿美元，年复合成长率为 10.77%。

主要市场统计数据
基准年 2025 22.9亿美元
预计年份：2026年 25.2亿美元
预测年份 2032 47亿美元
复合年增长率 (%) 10.77%

本报告总结了甲癣的当前临床和商业性格局，指出了未满足的需求、相关人员的趋势以及不断发展的治疗途径。

由于人口老化、合併症盛行率增加以及患者对治疗耐受性和便利性的期望不断变化，甲癣仍然是临床和商业性持续面临的挑战。临床医生在诊断甲癣时面临许多困难，因为其症状不典型且病因复杂；而患者往往由于顾虑美观或既往治疗失败而延误就医，导致巨大的未满足医疗需求。

治疗创新、製剂进步和医疗保健服务的演变如何重新定义甲癣的治疗选择、药物依从性和商业化？

随着治疗方法的创新与不断变化的患者期​​望和医疗服务模式相融合，甲癣的治疗格局正在经历一场变革。治疗方法正从单一疗法转向综合治疗方法，结合外用药物、口服药物、医疗设备介入和支持性护理，以提高疗效和病人依从性。这种多管齐下的策略正在重塑临床医生选择轻症和重症甲癣治疗方法的方式，以及製药公司在临床讯息中如何定位其产品的优势。

评估美国关税措施在 2025 年之前对供应链、采购和购买的影响，因为这些措施将重塑成本结构和商业化选择。

美国计划在2025年前实施新的关税措施，将对皮肤科和抗真菌产品的供应链、筹资策略和定价动态连锁反应。从海外采购活性成分、添加剂或成品的製造商正在重新审视其采购地点和合约条款，以降低进口关税和清关相关的风险。这些调整往往会导致供应计划的改变，进而可能影响分销点的产品供应和库存缓衝。

透过多方面的细分，我们旨在明确患者特征、治疗模式和分布趋势，从而为制定有针对性的临床和商业策略做出贡献。

详细的市场细分揭示了临床偏好、患者行为和分销趋势的轮廓，这些都指南产品开发和市场进入策略。无论药物类型如何，治疗方法的组合多种多样，从联合治疗和雷射疗法到口服和外用疗法，每种疗法都有其独特的疗效、安全性和依从性特征，这些都会影响治疗方法的治疗方法通常与疾病的严重程度、合併症的负担以及预期疗效（无论是短期疗效还是长期疗效）密切相关。

本研究评估了美洲、欧洲、中东和非洲以及亚太地区的区域监管多样性、医疗保健资金来源和分销管道成熟度如何影响产品采用和获取趋势。

区域趋势对塑造临床实践模式、监管通路和分销基础设施至关重要，进而影响产品的普及应用。在美洲，完善的临床网络、广泛的门诊服务以及活跃的药房管道，为创新型外用製剂和全身疗法提供了良好的环境，使其能够在可靠的安全性和疗效对比证据的支持下，迅速渗透到临床实践中。报销机制和支付方的审查往往侧重于价值和真实世界的临床结果，从而影响处方集制定和合约条款。

成熟新兴企业之间的竞争定位，是由临床差异化、製剂研发领先地位、策略联盟和供应链韧性所驱动的。

甲癣领域的竞争格局围绕着临床差异化、製剂创新以及在真实临床环境中证明疗效持续性。成熟的新兴企业主要企业凭藉丰富的临床试验经验、深厚的监管知识以及与关键意见领袖 (KOL) 和支付方建立的良好关係，保持着竞争优势。同时，小规模的专科製药公司和生物技术参与企业致力于透过专注于製剂科学和新型作用机制，在细分市场中站稳脚跟。

为製造商和相关人员提供切实可行的策略方法，将证据产生、配方技术进步和供应链韧性相结合，以确保可持续的竞争优势。

产业领导企业应优先考虑协作方式，将临床证据的取得、製剂创新和供应链紧急时应对计画有机结合。儘早投资于直接对照试验和真实世界研究，以评估治疗效果的可持续性、老年患者的安全性以及患者报告的疗效，将有助于增强与支付方谈判和与临床医生合作时的价值提案。同时，优化製剂以缩短疗程并提高药物对指甲的渗透性，将显着提高患者的用药依从性和满意度，从而创造出引人入胜的商业性故事。

透过结合相关人员访谈、系统性文献综述和检验的严格混合方法研究设计，我们提供了可操作的临床和商业性见解，同时清楚地指出了它们的局限性。

本研究途径结合了对皮肤科医生、药剂师、供应链经理和支付方代表的结构化访谈，以及对监管申报文件、临床试验註册资讯和同行评审文献的广泛二次分析。主要研究着重于半结构化访谈，以捕捉关于治疗决策因素、未满足的需求和营运挑战的细微观点，从而能够与公开的临床证据和政策文件进行定性检验。

本报告总结了临床创新、供应链韧性和实证商业化对于甲癣治疗持续进展的策略意义。

总之，甲癣仍然是一个临床需求极高的领域，活性成分、製剂技术和综合治疗方法的进步正在重塑治疗选择。相关人员的成功需要权衡临床疗效、老年和合併症患者群体的安全性、不断变化的销售管道以及各地不同的法规等复杂因素。策略性地关注能够证明治疗效果持续、以患者为中心的便利性和明确的经济价值的证据，对于确保临床医生采纳和支付方支持至关重要。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：以药物类型分類的甲癣治疗市场

  • 联合治疗
  • 雷射疗法
  • 口服疗法
  • 局部治疗

第九章：以活性成分分類的甲癣治疗市场

  • 阿莫罗芬
  • 环吡罗
  • 依芬那康唑
  • Fluconazole
  • Itraconazole
  • 塔巴勃洛尔
  • Terbinafine

第十章：以剂型分類的甲癣治疗市场

  • 奶油
  • 凝胶
  • 指甲油
  • 解决方案
  • 片剂和胶囊

第十一章：依治疗环境分類的甲癣治疗市场

  • 居家照护
  • 住院治疗
  • 门诊治疗

第十二章：甲癣治疗市场：依年龄组别划分

  • 18-65岁
  • 65岁或以上
  • 18岁以下

第十三章：甲癣治疗市场：性别

  • 女士
  • 男性

第十四章：依疾病严重程度分類的甲癣治疗市场

  • 轻度至中度
  • 復发
  • 严重

第十五章：甲癣治疗市场：依分销管道划分

  • 医院药房
  • 网路药房
  • 零售药房

第十六章：甲癣治疗市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十七章：甲癣治疗市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十八章：甲癣治疗市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十九章：美国甲癣治疗市场

第二十章：中国甲癣治疗市场

第21章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy's Laboratories Ltd.
  • Galderma SA
  • Johnson & Johnson Services, Inc.
  • LEO Pharma A/S
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: MRR-FD3F12D54166

The Onychomycosis Treatment Market was valued at USD 2.29 billion in 2025 and is projected to grow to USD 2.52 billion in 2026, with a CAGR of 10.77%, reaching USD 4.70 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.29 billion
Estimated Year [2026] USD 2.52 billion
Forecast Year [2032] USD 4.70 billion
CAGR (%) 10.77%

Framing the modern clinical and commercial landscape of onychomycosis to illuminate unmet needs, stakeholder dynamics, and evolving treatment pathways

Onychomycosis presents a persistent clinical and commercial challenge driven by aging populations, increasing comorbidity prevalence, and evolving patient expectations for tolerability and convenience. Clinicians face diagnostic complexity due to atypical presentations and mixed etiologies, while patients often delay seeking care because of perceived cosmetic concerns and previous treatment failures, creating a landscape where unmet needs remain pronounced.

Recent advances in therapeutic modalities, including more targeted topical antifungals, innovations in oral agents, and adjunctive technologies like laser interventions, have diversified the care pathway and expanded options for different patient profiles. Nevertheless, gaps persist in adherence, long-term relapse prevention, and real-world effectiveness data. Payers and providers are converging on value-driven decision criteria, emphasizing safety profiles, treatment duration, and demonstrable improvements in patient-reported outcomes.

This introduction synthesizes the clinical context, stakeholder dynamics, and the shifting treatment paradigm while setting the stage for deeper exploration of regulatory, economic, and commercial forces that shape product development, market access strategies, and competitive positioning in onychomycosis care.

How therapeutic innovation, formulation advances, and care delivery evolution are redefining treatment choice, adherence, and commercialization in onychomycosis care

The onychomycosis landscape is undergoing transformative shifts as therapeutic innovation intersects with changing patient expectations and delivery models. Treatment approaches are moving beyond single-modality prescriptions toward integrated regimens that combine topical agents, oral therapies, device-based interventions, and supportive measures to improve efficacy and adherence. This multidimensional strategy reframes how clinicians select treatments for mild versus severe disease and how manufacturers position product benefits in clinical messaging.

Simultaneously, investment in formulation science has elevated the role of penetration enhancers, novel vehicle systems, and application convenience, which together address long-standing barriers such as slow nail penetration and prolonged treatment durations. Emerging active ingredients and combination strategies are being tested to reduce relapse rates and improve cure durability, while safety and drug-drug interaction profiles remain central to adoption in populations with polypharmacy, particularly older adults.

On the delivery front, digital channels and telehealth services are reshaping patient access and follow-up, enabling earlier intervention and improved adherence monitoring. Pharmacy models are adapting to this shift, with online pharmacies and home care pathways gaining traction alongside traditional hospital and retail channels. These transformative trends create both opportunities for differentiated clinical value and challenges for market entry, necessitating integrated commercialization plans that account for regulatory nuance, payer expectations, and patient-centric positioning.

Assessing the supply chain, sourcing, and procurement consequences of United States tariff measures through 2025 that are reshaping cost structures and commercialization choices

The introduction of new tariff measures in the United States through 2025 has created a ripple effect across supply chains, procurement strategies, and pricing dynamics for dermatology and antifungal products. Manufacturers that source active pharmaceutical ingredients, excipients, or finished goods internationally are reassessing sourcing footprints and contractual terms to mitigate import duties and customs-related timeline risks. These adjustments often translate into supply planning changes that can affect product availability and inventory buffers at distribution points.

Short-term responses have included shifting component sourcing to domestic or low-tariff jurisdictions, renegotiating supplier agreements to include tariff-sharing clauses, and selectively increasing onshore inventory for critical SKUs. Over time, firms are evaluating nearshore manufacturing and localized formulation facilities as structural responses to tariff-driven cost pressures. These strategic investments reduce exposure to trade volatility but require capital allocation decisions that influence product launch timetables and margin structures.

Payers and procurement teams are also reacting by tightening contracting terms, emphasizing value-based arrangements, and scrutinizing total cost of therapy. Clinical leaders and purchasing departments may favor therapeutics with differentiated safety or adherence advantages that justify adjusted pricing in light of increased supply costs. The net effect is a heightened premium on supply chain resilience, commercial flexibility, and the capacity to communicate clear value propositions that absorb the operational impacts of tariff-driven cost changes without undermining access or clinician trust.

Illuminating patient profiles, therapeutic formats, and distribution dynamics through multi-dimensional segmentation to inform targeted clinical and commercial strategies

Detailed segmentation reveals the contours of clinical preference, patient behavior, and distribution dynamics that inform product development and go-to-market strategies. Across drug type, the therapeutic mix ranges from combination therapy and laser therapy to oral therapy and topical therapy, with each modality carrying distinct efficacy, safety, and adherence profiles that influence clinician selection and patient acceptance. Treatment choice often correlates with disease severity, comorbidity burden, and the desire for rapid versus sustained outcomes.

Considering active ingredient differentiation, compounds such as amorolfine, ciclopirox, efinaconazole, fluconazole, itraconazole, tavaborole, and terbinafine exhibit varied mechanisms of action, pharmacokinetics, and safety considerations. These differences dictate labeling, contraindications, and monitoring needs, and they provide the basis for clinical positioning against competing therapies. Formulation matters as well: cream, gel, nail lacquer, solution, and tablet capsule formats change the patient experience, affect adherence, and present unique manufacturing and regulatory considerations.

Distribution channel analysis highlights the role of hospital pharmacy, online pharmacy, and retail pharmacy pathways in determining access, counseling opportunities, and point-of-sale dynamics. Treatment setting segmentation across home care, hospital inpatient, and outpatient clinic environments further guides how therapies are administered and supported, with implications for follow-up, adherence interventions, and reimbursement. Age group distinctions-18 to 65 years, above 65 years, and below 18 years-intersect with gender segments of female and male patients to shape epidemiologic trends and address age- or gender-specific safety concerns. Finally, disease severity categories of mild to moderate, recurrent, and severe act as primary drivers of therapeutic intensity and regimen selection. Synthesizing these segmentation layers allows stakeholders to identify target patient cohorts, tailor messaging, and prioritize clinical evidence generation that resonates with prescribers and payers alike.

Evaluating how regional regulatory diversity, healthcare financing, and channel maturity across the Americas, EMEA, and Asia-Pacific shape adoption and access dynamics

Regional dynamics are pivotal in shaping clinical practice patterns, regulatory pathways, and distribution infrastructures that affect product adoption. In the Americas, established clinical networks, broad outpatient access, and active pharmacy channels create an environment where both innovative topical formulations and systemic therapies can achieve rapid clinical uptake when supported by robust safety and comparative-effectiveness evidence. Reimbursement mechanisms and payer scrutiny tend to emphasize value and real-world outcomes, influencing formulary decisions and contracting approaches.

In Europe, Middle East & Africa, diverse regulatory frameworks and heterogeneous healthcare financing models mean that market entry and adoption trajectories vary significantly across jurisdictions. Centralized regulatory pathways coexist with localized reimbursement negotiations, requiring tailored launch strategies and region-specific evidence packages. Distribution models in this region range from hospital-centric procurement in some markets to thriving retail and online pharmacy ecosystems in others, affecting channel prioritization.

The Asia-Pacific region is characterized by a mix of high-volume patient populations, evolving clinical guidelines, and rapidly modernizing healthcare infrastructures. Local manufacturing capabilities, regulatory acceleration pathways in select markets, and growing telehealth penetration influence how therapies are evaluated and adopted. Across regions, cultural perceptions of dermatologic conditions, access to specialist care, and the maturity of pharmacy channels collectively determine patient engagement, diagnostic timeliness, and long-term management approaches. Understanding these regional nuances is essential for calibrating clinical development, regulatory submissions, and commercial deployment.

Competitive positioning driven by clinical differentiation, formulation leadership, strategic alliances, and supply chain resilience among established and emerging players

Competitive dynamics among leading and emerging companies in onychomycosis are centered on clinical differentiation, formulation innovation, and the ability to demonstrate durable outcomes in real-world settings. Established pharmaceutical developers maintain advantages through broad clinical trial experience, extensive regulatory knowledge, and existing relationships with key opinion leaders and payer bodies. At the same time, smaller specialty firms and biotech entrants are leveraging targeted approaches to formulation science and novel mechanisms of action to carve niche positions.

Strategic activity includes focused R&D investment in penetration enhancers and combination regimens, alliances with device manufacturers for adjunctive therapies, and partnerships that accelerate access to specialty pharmacy and digital adherence tools. Licensing agreements and regional distribution partnerships are common maneuvers to extend geographic reach while minimizing direct infrastructure investment. Additionally, companies are prioritizing the generation of patient-reported outcomes and health-economic evidence to support reimbursement discussions and to differentiate in crowded therapy classes.

Operational readiness-manufacturing scalability, quality control, and supply chain resilience-remains a critical competitive lever, especially as firms navigate tariff and procurement headwinds. Companies that integrate clinical differentiation with robust commercialization models and responsive distribution strategies are positioned to secure clinician trust and payer support, while maintaining flexibility to pivot as evidence or regulatory landscapes evolve.

Practical strategic initiatives for manufacturers and stakeholders to align evidence generation, formulation advances, and supply chain resilience for sustained competitive advantage

Industry leaders should prioritize a coordinated approach that aligns clinical evidence generation, formulation innovation, and supply chain contingency planning. Early investments in head-to-head and real-world studies that capture durability of response, safety in older adults, and patient-reported outcomes will strengthen value propositions during payer negotiations and clinician engagement. Concurrently, optimizing formulations to reduce treatment duration and enhance nail penetration can materially improve adherence and patient satisfaction, creating a compelling commercial narrative.

On the operational front, diversifying sourcing strategies, exploring nearshore manufacturing options, and implementing tariff-mitigation clauses with suppliers will reduce exposure to trade volatility and support stable supply. Commercial teams must also cultivate channel-specific strategies that reflect the nuances of hospital pharmacy, online pharmacy, and retail pharmacy operations, while ensuring that patient support programs and digital adherence tools are integrated into launch plans.

Finally, leaders should pursue selective partnerships with device innovators, digital health providers, and regional distributors to accelerate access in priority markets. These combined actions-evidence-focused clinical programs, formulation differentiation, resilient sourcing, and strategic alliances-will enable organizations to capture clinical credibility, manage cost pressures, and deliver patient-centered solutions that stand out in a competitive therapeutic area.

A rigorous mixed-methods research design combining stakeholder interviews, systematic literature review, and triangulation to provide actionable clinical and commercial insights with transparent limitations

The research approach combined structured primary engagement with dermatology clinicians, pharmacists, supply chain managers, and payer representatives alongside extensive secondary analysis of regulatory filings, clinical trial registries, and peer-reviewed literature. Primary research prioritized semi-structured interviews to capture nuanced perspectives on treatment decision drivers, unmet clinical needs, and operational challenges, enabling qualitative triangulation with publicly available clinical evidence and policy documents.

Secondary research involved systematic review of published clinical trials, safety reports, and formulation studies to validate mechanistic claims and comparative tolerability profiles. Data synthesis emphasized evidence quality, methodological transparency, and relevance to real-world clinical practice. Triangulation techniques were applied to reconcile differing stakeholder viewpoints and to identify consensus areas as well as evidence gaps that warrant further study.

Quality assurance measures included independent review of data extraction, standardized interview protocols to reduce bias, and documentation of limitations such as regional heterogeneity in clinical practice and variability in long-term outcome reporting. The methodology was designed to foreground actionable insights while acknowledging areas where additional primary data collection or longer-term observational studies would strengthen confidence in specific clinical or economic conclusions.

Summarizing the strategic implications of clinical innovation, supply chain resilience, and evidence-driven commercialization for sustained progress in onychomycosis care

In conclusion, onychomycosis remains an area of high clinical need where advances in active ingredients, formulation technologies, and integrated treatment approaches are reshaping therapeutic choices. Stakeholders must navigate a complex interplay of clinical efficacy, safety considerations in older and comorbid populations, distribution channel evolution, and regional regulatory diversity to succeed. Strategic emphasis on evidence that demonstrates durable outcomes, patient-centered convenience, and clear economic value will be decisive in securing clinician adoption and payer support.

Operational resilience-particularly in supply chain sourcing and tariff mitigation-will influence product availability and commercial robustness as geopolitical and trade factors continue to evolve. Companies that combine clinical differentiation with pragmatic commercialization plans, targeted regional strategies, and partnerships to enhance access will be best positioned to address unmet needs and build lasting therapeutic franchises. Continued investment in real-world evidence and patient engagement will remain central to translating innovation into meaningful improvements in patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Onychomycosis Treatment Market, by Drug Type

  • 8.1. Combination Therapy
  • 8.2. Laser Therapy
  • 8.3. Oral Therapy
  • 8.4. Topical Therapy

9. Onychomycosis Treatment Market, by Active Ingredient

  • 9.1. Amorolfine
  • 9.2. Ciclopirox
  • 9.3. Efinaconazole
  • 9.4. Fluconazole
  • 9.5. Itraconazole
  • 9.6. Tavaborole
  • 9.7. Terbinafine

10. Onychomycosis Treatment Market, by Formulation

  • 10.1. Cream
  • 10.2. Gel
  • 10.3. Nail Lacquer
  • 10.4. Solution
  • 10.5. Tablet Capsule

11. Onychomycosis Treatment Market, by Treatment Setting

  • 11.1. Home Care
  • 11.2. Hospital Inpatient
  • 11.3. Outpatient Clinic

12. Onychomycosis Treatment Market, by Age Group

  • 12.1. 18 To 65 Years
  • 12.2. Above 65 Years
  • 12.3. Below 18 Years

13. Onychomycosis Treatment Market, by Gender

  • 13.1. Female
  • 13.2. Male

14. Onychomycosis Treatment Market, by Disease Severity

  • 14.1. Mild To Moderate
  • 14.2. Recurrent
  • 14.3. Severe

15. Onychomycosis Treatment Market, by Distribution Channel

  • 15.1. Hospital Pharmacy
  • 15.2. Online Pharmacy
  • 15.3. Retail Pharmacy

16. Onychomycosis Treatment Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Onychomycosis Treatment Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Onychomycosis Treatment Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. United States Onychomycosis Treatment Market

20. China Onychomycosis Treatment Market

21. Competitive Landscape

  • 21.1. Market Concentration Analysis, 2025
    • 21.1.1. Concentration Ratio (CR)
    • 21.1.2. Herfindahl Hirschman Index (HHI)
  • 21.2. Recent Developments & Impact Analysis, 2025
  • 21.3. Product Portfolio Analysis, 2025
  • 21.4. Benchmarking Analysis, 2025
  • 21.5. Bausch Health Companies Inc.
  • 21.6. Bayer AG
  • 21.7. Dr. Reddy's Laboratories Ltd.
  • 21.8. Galderma S.A.
  • 21.9. Johnson & Johnson Services, Inc.
  • 21.10. LEO Pharma A/S
  • 21.11. Novartis AG
  • 21.12. Pfizer Inc.
  • 21.13. Sanofi S.A.
  • 21.14. Sun Pharmaceutical Industries Ltd.
  • 21.15. Teva Pharmaceutical Industries Ltd.
  • 21.16. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 15. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 16. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY LASER THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ORAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TOPICAL THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AMOROLFINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CICLOPIROX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY EFINACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FLUCONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ITRACONAZOLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TAVABOROLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TERBINAFINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY NAIL LACQUER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TABLET CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL INPATIENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY 18 TO 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ABOVE 65 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY BELOW 18 YEARS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY MILD TO MODERATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RECURRENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SEVERE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 188. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 190. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 218. G7 ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY ACTIVE INGREDIENT, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY TREATMENT SETTING, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISEASE SEVERITY, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ONYCHOMYCOSIS TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)